| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNNT2 |
| Uniprot No | P45379-11 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-285aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MSDIEEVVEE YEEEEQEEAA VEEQEEAAEE DAEAEAETEE TRAEEDEEEE EAKEAEDGPM EESKPKPRSF MPNLVPPKIP DGERVDFDDI HRKRMEKDLN ELQALIEAHF ENRKKEEEEL VSLKDRIERR RAERAEQQRI RNEREKERQN RLAEERARRE EEENRRKAED EARKKKALSN MMHFGGYIQK TERKSGKRQT EREKKKKILA ERRKVLAIDH LNEDQLREKA KELWQSIYNL EAEKFDLQEK FKQQKYEINV LRNRINDNQK VSKTRGKAKV TGRWK |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNNT2重组蛋白的3篇代表性文献摘要概括：
1. **文献名称**：*Recombinant human cardiac troponin T: purification and functional characterization*
**作者**：Murakami K et al.
**摘要**：研究报道了人源TNNT2重组蛋白在大肠杆菌中的高效表达与纯化方法，并验证其与肌钙蛋白I、C复合物的结合能力及钙离子依赖性调节功能，为心肌收缩机制研究提供工具。
2. **文献名称**：*TNNT2 mutations in dilated cardiomyopathy: impact of recombinant protein expression on sarcomere function*
**作者**：Carballo S et al.
**摘要**：通过构建携带扩张型心肌病相关TNNT2突变的重组蛋白，分析突变对肌节结构和钙敏感性的影响，揭示特定氨基酸改变导致心肌收缩力异常的分子机制。
3. **文献名称**：*High-throughput screening of TNNT2-targeted compounds using recombinant protein-based assays*
**作者**：Liu Y et al.
**摘要**：开发基于TNNT2重组蛋白的体外药物筛选平台，筛选出可调节心肌收缩力的小分子化合物，为心力衰竭治疗药物研发提供新策略。
(注：以上文献信息为模拟概括，实际引用需核对具体论文数据)
**Background of TNNT2 Recombinant Protein**
Troponin T type 2 (TNNT2) is a key protein component of the cardiac muscle troponin complex, which regulates calcium-dependent contraction in striated muscle. Encoded by the *TNNT2* gene located on human chromosome 1q32. it serves as the tropomyosin-binding subunit of the troponin complex, anchoring the complex to thin filaments and modulating interactions between actin and myosin during excitation-contraction coupling. TNNT2 is critical for maintaining normal cardiac function, and mutations in this gene are associated with inherited cardiomyopathies, including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and restrictive cardiomyopathy, as well as arrhythmogenic disorders.
Recombinant TNNT2 protein is produced using biotechnological methods, such as expression in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian or insect cells), followed by purification and functional validation. This engineered protein retains the structural and functional properties of native TNNT2. enabling its use in studying molecular mechanisms of cardiac diseases, drug screening, and diagnostic applications. For example, recombinant TNNT2 aids in investigating how specific mutations disrupt sarcomere function, testing potential therapeutic compounds targeting troponin dynamics, or developing assays to detect cardiac troponin isoforms in clinical settings (e.g., myocardial infarction biomarkers).
Research involving TNNT2 recombinant protein also contributes to understanding tissue-specific splicing variants and post-translational modifications that influence cardiac physiology. Its role in disease models and regenerative medicine underscores its importance in advancing cardiovascular therapeutics and precision medicine approaches.
×
